Combining SGLT-2 Inhibitors and GLP-1–Receptor Agonists for CV Risk Reduction in Type 2 Diabetes

Abstract

There is much excitement about the emerging evidence on sodium–glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1)–receptor